[SL2] Will cell therapy for hematological malignancy be a panacea?
Malcolm K Brenner is the Founding Director, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital and the Fayez Sarofim Distinguished Service Professor at BCM.
Dr. Brenner obtained his medical degrees and his PhD from the University of Cambridge, England. He moved to the USA in 1990, to head the Cell and Gene Therapy Program at St Jude Children's Research Hospital, where his group performed the first human gene transfer studies outside of the NIH and the first anywhere to use marrow stem cells as the target. In 1998 he moved to his current position. Over the past 30 years, Dr. Brenner has devoted his career as a physician-scientist to the field of stem cell transplantation through the therapeutic use of T cell immunologic approaches and genetic engineering strategies, particularly in the treatment of cancer. He served as Editor-in-Chief of Molecular Therapy and as former President of the American Society for Gene and Cell Therapy (ASGCT) and of the International Society for Cell Therapy. Dr. Brenner has earned widespread recognition for his scientific achievements and leadership in the field, including the ASGCT Outstanding Achievement Award, Human Gene Therapy’s Pioneer Award, the American Society of Hematology Mentor Award and the European Society of Gene and Cell Therapy Outstanding Achievement award.
For his contributions to the field, Dr. Brenner has been elected a member of the American Association of Physicians and of the National Academy of Medicine
Dr. Brenner obtained his medical degrees and his PhD from the University of Cambridge, England. He moved to the USA in 1990, to head the Cell and Gene Therapy Program at St Jude Children's Research Hospital, where his group performed the first human gene transfer studies outside of the NIH and the first anywhere to use marrow stem cells as the target. In 1998 he moved to his current position. Over the past 30 years, Dr. Brenner has devoted his career as a physician-scientist to the field of stem cell transplantation through the therapeutic use of T cell immunologic approaches and genetic engineering strategies, particularly in the treatment of cancer. He served as Editor-in-Chief of Molecular Therapy and as former President of the American Society for Gene and Cell Therapy (ASGCT) and of the International Society for Cell Therapy. Dr. Brenner has earned widespread recognition for his scientific achievements and leadership in the field, including the ASGCT Outstanding Achievement Award, Human Gene Therapy’s Pioneer Award, the American Society of Hematology Mentor Award and the European Society of Gene and Cell Therapy Outstanding Achievement award.
For his contributions to the field, Dr. Brenner has been elected a member of the American Association of Physicians and of the National Academy of Medicine
抄録パスワード認証
抄録の閲覧にはパスワードが必要です。パスワードを入力して認証してください。パスワードは「第81回日本血液学会学術集会 ポケットプログラムのプログラム検索・スケジュール登録アプリのご案内ページ」に記載してあります。